Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <scp>AC‐TIVE</scp> study, an <scp>Italian nationwide survey</scp>Marco Merlo, Gianfranco Sinagra, Francesca Longo et al.|European Journal of Heart Failure|2022Cited by 91
Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosisAldostefano Porcari, Marco Merlo, Maria Cristina Morelli et al.|European Journal of Heart Failure|2022Cited by 69
Value of the <scp>HFA‐PEFF</scp> and <scp> H <sub>2</sub> FPEF </scp> scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosisDaniela Tomasoni, Marco Metra, Edoardo Pancaldi et al.|European Journal of Heart Failure|2022Cited by 43